Lantheus (NASDAQ:LNTH) Stock Sold Off by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros, Jr. disclosed selling $1,001–$15,000 of Lantheus shares on October 14 from a trust account.
• Lantheus reported quarterly EPS of $1.68, beating the $1.23 consensus, and revenue of $389.91 million, above estimates; revenue rose 1.5% year over year.
• Analyst sentiment was mostly cautious: 11 analysts rated the stock Hold and three rated it Buy, with a consensus price target of $107.44.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Lantheus stock on October 14th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 11/2/2026.
• Purchased $1,001 - $15,000 in shares of argenex NASDAQ: ARGX on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Illumina NASDAQ: ILMN on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 10/27/2026.
• Sold $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 10/27/2026.
• Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 10/27/2026.
• Purchased $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Micron Solutions OTCMKTS: MICR on 10/21/2026.
• Sold $1,001 - $15,000 in shares of Ciena NYSE: CIEN on 10/21/2026.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 10/21/2026.

Lantheus Trading Down 0.0%

Shares of LNTH opened at $101.60 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.25 and a quick ratio of 3.06. The firm has a 50 day simple moving average of $100.30 and a 200-day simple moving average of $92.57. Lantheus Holdings, Inc. has a 1-year low of $51.47 and a 1-year high of $111.86. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of 25.02 and a beta of 0.01.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.45. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The firm had revenue of $389.91 million during the quarter, compared to the consensus estimate of $355.74 million. During the same period in the previous year, the firm posted $1.27 EPS. The company's quarterly revenue was up 1.5% compared to the same quarter last year. Equities analysts forecast that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LNTH. Truist Financial downgraded Lantheus from a "buy" rating to a "hold" rating and dropped their price target for the stock from $125.00 to $102.50 in a research report on Monday, August 3rd. B. Riley Financial downgraded Lantheus from a "buy" rating to a "hold" rating in a research report on Monday, August 17th. Leerink Partners set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. William Blair set a $102.50 price objective on Lantheus in a research report on Monday, August 3rd. Finally, TD Cowen cut Lantheus from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $107.44.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently added to or reduced their stakes in the business. ABS Investment Management LLC purchased a new position in Lantheus during the second quarter worth about $232,974,000. Western Wealth Management LLC purchased a new stake in Lantheus in the first quarter valued at approximately $25,000. USA Financial Formulas acquired a new position in Lantheus during the third quarter worth approximately $41,000. Allworth Financial LP acquired a new position in Lantheus during the second quarter worth approximately $49,000. Finally, Bessemer Group Inc. increased its position in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 354 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Lantheus

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company's products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.